Respiratory Status of Seventy-Four Habitual Marijuana Smokers

CHEST Journal ◽  
1980 ◽  
Vol 78 (5) ◽  
pp. 699-706 ◽  
Author(s):  
Donald P. Tashkin ◽  
Barry M. Calvarese ◽  
Michael S. Simmons ◽  
Bertrand J. Shapiro
Keyword(s):  
Respiratory Status

scholarly journals Delayed pulmonary embolism after COVID-19 pneumonia: a case report

2020 ◽  
Author(s):  
Mohamad Kanso ◽  
Thomas Cardi ◽  
Halim Marzak ◽  
Alexandre Schatz ◽  
Loïc Faucher ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intensive Care Unit ◽  
Pulmonary Embolism ◽  
Acute Pulmonary Embolism ◽  
Index Hospitalization ◽  
Rt Pcr ◽  
Moderate Severity ◽  
Respiratory Status ◽  
Case Summary ◽  
Pcr Test

Abstract Background  Since the onset of the COVID-19 pandemic, several cardiovascular manifestations have been described. Among them, venous thromboembolism (VTE) seems to be one of the most frequent, particularly in intensive care unit patients. We report two cases of COVID-19 patients developing acute pulmonary embolism (PE) after discharge from a first hospitalization for pneumonia of moderate severity. Case summary  Two patients with positive RT-PCR test were initially hospitalized for non-severe COVID-19. Both received standard thromboprophylaxis during the index hospitalization and had no strong predisposing risk factors for VTE. Few days after discharge, they were both readmitted for worsening dyspnoea due to PE. One patient was positive for lupus anticoagulant. Discussion  Worsening respiratory status in COVID-19 patients must encourage physicians to search for PE since SARS-CoV-2 infection may act as a precipitant risk factor for VTE. Patients may thus require more aggressive and longer thromboprophylaxis after COVID-19 related hospitalization.

scholarly journals Visual assessment versus computer-assisted gray scale analysis in the ultrasound evaluation of neonatal respiratory status

PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0202397 ◽  
Author(s):  
Francesco Raimondi ◽  
Fiorella Migliaro ◽  
Luisa Verdoliva ◽  
Diego Gragnaniello ◽  
Giovanni Poggi ◽  
...  
Keyword(s):  
Visual Assessment ◽  
Computer Assisted ◽  
Scale Analysis ◽  
Gray Scale ◽  
Respiratory Status ◽  
Ultrasound Evaluation

scholarly journals Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study

2021 ◽  
Author(s):  
Yuichi Kojima ◽  
Sho Nakakubo ◽  
Keisuke Kamada ◽  
Yu Yamashita ◽  
Nozomu Takei ◽  
...  
Keyword(s):  
Chronic Renal Disease ◽  
Secondary Infection ◽  
University Hospital ◽  
Rank Test ◽  
Logistic Regression Models ◽  
Respiratory Status ◽  
Kaplan Meier ◽  
Single Center Study ◽  
Significant Difference ◽  
All Cause Mortality

SummaryBackgroundAlthough biological agents, tocilizumab and baricitinib, have been shown to improve the outcomes of patients with COVID-19, a comparative evaluation has not been performed.MethodsA retrospective, single-center study was conducted using the data of patients with COVID-19 admitted to the Hokkaido University hospital between April 2020 and September 2021, who were treated with tocilizumab or baricitinib. The clinical characteristics of patients who received each drug were compared. Univariate and multivariate logistic regression models were performed against the outcomes of all-cause mortality and the improvement in respiratory status. The development of secondary infection events was analyzed using the Kaplan–Meier analysis and the log-rank test.ResultsThe use of tocilizumab or baricitinib was not associated with all-cause mortality and the improvement in respiratory status within 28 days of drug administration. Age, chronic renal disease, and comorbid respiratory disease were independent prognostic factors for all-cause mortality, while anti-viral drug use and severity of COVID-19 at baseline were associated with the improvement in respiratory status. There was no significant difference in the infection-free survival between patients treated with tocilizumab and those with baricitinib.ConclusionThere were no differences in efficacy and safety between tocilizumab and baricitinib for the treatment of COVID-19.

scholarly journals The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular Atrophy

2021 ◽  
Author(s):  
Evrim Hepkaya ◽  
Ayse Ayzit Kilinc ◽  
İpek Ülkersoy ◽  
Azer Kilic Baskan ◽  
Hüseyin Arslan ◽  
...  
Keyword(s):  
Spinal Muscular Atrophy ◽  
Nutritional Support ◽  
Hospital Admissions ◽  
Muscular Atrophy ◽  
Pulmonary Involvement ◽  
Early Initiation ◽  
Randomised Study ◽  
Global Consensus ◽  
Respiratory Status ◽  
Age Of Diagnosis

Introduction : Pulmonary involvement is the main prognostic factor in children with spinal muscular atrophy (SMA). Nusinersen, a new treatment modality, is being evaluated in recent studies, although the respiratory part has not yet been clarified. We aimed to reveal the effects of nusinersen on the respiratory functions of patients with spinal muscular atrophy (SMA). Methods : In this single-center randomised study, conducted between June 2020/July 2021, patients with SMA were evaluated before and during nusinersen therapy. Data were collected on respiratory status, nutritional support, motor involvement, and other comorbidities that may affect the disease prognosis. Results : Patients with the number of 43 (18 type1, 12 type2, 13 type3) with a mean age of diagnosis of 10 months (range 1.5-192) and 24 months (3-219) at the start of nusinersen therapy were included. An improvement in respiratory status was noted in six patients between the second and third assessment. SMN2 copy numbers were significantly associated with better prognosis. Early initiation of nusinersen was significantly correlated with reduced hospital admissions. Nutritional support and weight gain were remarkable in the ventilatory supported group. A significant improvement was observed in motor functions, and chop-intend scores were statistically significantly higher in non-tracheostomized group (p<0.005). Conclusion : We think that nusinersen’s effect may be significant with early initiation and continuation of treatment. Improvements in respiratory functions noted in our study require to be supported with future long-term studies considering the overall genetic and environmental status, even the cost-effectiveness,to make a global consensus on nusinersen therapy.

Sign in / Sign up

Export Citation Format

Share Document